Dosage of β-adrenergic blockers after myocardial infarction

American Journal of Health-System Pharmacy

Volumn 60, Issue 23, 2003, Pages 2471-2474

  Anderson, Sara C ^a   Jones, William N ^b,c   Evanko, Tara M ^b  

^a CARL T HAYDEN VA MEDICAL CENTER   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Atenolol; Cardiac drugs; Dosage; Metoprolol tartrate; Myocardial infarction; Propranolol; Sympatholytic agents

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL TARTRATE; PROPRANOLOL; TIMOLOL MALEATE;

CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG TOLERABILITY; FOLLOW UP; HEALTH CENTER; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MEDICAL RECORD; MORTALITY; PRIORITY JOURNAL; PULSE RATE; REVIEW; SYSTOLIC BLOOD PRESSURE; RETROSPECTIVE STUDY; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 1542754960     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.23.2471     Document Type: Review

References (14)

1. Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. JAMA. 1981; 246:2073-4.
2. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304:801-7.
3. Pedersen TR. Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction. N Engl J Med. 1985; 313:1055-8.
4. Hjalmarson A, Elmfeldt D, Herlitz J et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981; 2:823-7.
5. MIAMI Trial Research Group. Metoprolol in Acute Myocardial Infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985; 6:199-226.
6. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. 1986; 2:57-66.
7. Dargie HJ. Effect of carvedilol on outcomes after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385-90.
8. White CM. Prevention of suboptimal beta-blocker treatment in patients with myocardial infarction. Ann Pharmacother. 1999; 33:1063-72.
9. Viskin S, Kitzis I, Lev E et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol. 1995; 25:1327-32.
10. Marciniak TA, Ellerbeck EF, Radford MJ et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA. 1998; 279:1351-7.
11. American College of Cardiology. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). www.acc.org/clinical/ guidelines/nov96/1999/index.htm (accessed 2003 May 21).
12. Gundersen T, Abrahamsen AM, Kjekshus J et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving myocardial infarction. Circulation. 1982; 66:1179-84.
13. Rochon PA, Tu JV, Anderson GM et al. Rate of heart failure and 1-year survival for older people receiving low-dose β-blocker therapy after myocardial infarction. Lancet. 2000; 356:639-44.
14. Barron HV, Viskin S, Lundstrom RJ et al. β-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. Arch Intern Med. 1998; 158:449-53.